Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18206724 | 1.00 | HSD17B10 (0.55) | HSD17B10SMN1; SMN2KMT2APOLBNPC1 | |
| SCHEMBL23397608 | 1.00 | HSD17B10 (0.55) | HSD17B10SMN1; SMN2KMT2APOLBNPC1 | |
| SCHEMBL8274222 | 0.87 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2KMT2APOLBNPC1 | |
| SCHEMBL14268224 | 0.87 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2KMT2APOLBNPC1 | |
| SCHEMBL19414808 | 0.84 | HSD17B10 (0.61) | HSD17B10SMN1; SMN2KMT2APOLBNPC1 | |
| SCHEMBL7286305 | 0.84 | HSD17B10 (0.61) | HSD17B10SMN1; SMN2KMT2APOLBNPC1 | |
| SCHEMBL895773 | 0.84 | HSD17B10 (0.61) | HSD17B10SMN1; SMN2KMT2APOLBNPC1 | |
| Hydrochloric Acid SCHEMBL28874591 | 0.83 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2KMT2APOLBNPC1 | |
| SCHEMBL18815769 | 0.83 | KLK7 (0.51) | HSD17B10SMN1; SMN2KMT2ANPC1KLK7 | |
| SCHEMBL18815771 | 0.83 | KLK7 (0.51) | HSD17B10SMN1; SMN2KMT2ANPC1KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020386-B2 | Methods and compositions for preventing opioid abuse | ALBANY MOLECULAR RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-10695342-B2 | Methods and compositions for preventing opioid abuse | ALBANY MOLECULAR RESEARCH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10226456-B2 | Methods and compositions for preventing opioid abuse | 3ST RESEARCH LLC (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-08 | — | — | US | disclosed |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-01 | — | — | US | disclosed |
| US-20160326182-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226456-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | HSD17B10 1111/4885SMN1; SMN2 252/4885KMT2A 3110/4885 |
| US-10695342-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | HSD17B10 1111/4885SMN1; SMN2 252/4885KMT2A 3110/4885 |
| US-11020386-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | HSD17B10 1111/4885SMN1; SMN2 252/4885KMT2A 3110/4885 |
| US-20160326182-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | HSD17B10 1111/4885SMN1; SMN2 252/4885KMT2A 3110/4885 |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | HSD17B10 1111/4885SMN1; SMN2 252/4885KMT2A 3110/4885 |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | HSD17B10 1111/4885SMN1; SMN2 252/4885KMT2A 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.